New drug cocktail aims to fight Hard-to-Treat liver cancers
NCT ID NCT05775159
First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This phase 2 trial is testing several new immunotherapy drugs, alone or combined with standard chemotherapy, in people with advanced liver or bile duct cancer. The goal is to see if these combinations can shrink tumors or slow the disease. About 294 adults whose cancer has spread or cannot be removed by surgery will participate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Volrustomig, Rilvegostomig, Bevacizumab, Lenvatinib, Gemcitabine, Cisplatin
- What this could lead to
- If successful, this trial could point toward more effective treatment options for advanced liver and bile duct cancers, potentially improving tumor shrinkage and delaying disease progression.
- What could go wrong
- This is an early phase 2 trial with a small number of participants, so results may not apply to all patients. The drug combinations may cause significant side effects, and there is no guarantee of benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Birmingham, Alabama, 35233, United States
-
Research Site
Los Angeles, California, 90089, United States
-
Research Site
Orange, California, 92868, United States
-
Research Site
Kansas City, Kansas, 66103, United States
-
Research Site
New York, New York, 10065, United States
-
Research Site
Beijing, 100050, China
-
Research Site
Beijing, 100142, China
-
Research Site
Beijing, 101100, China
-
Research Site
Chengdu, 610000, China
-
Research Site
Chengdu, 610041, China
-
Research Site
Chongqing, 400030, China
-
Research Site
Fuzhou, 350007, China
-
Research Site
Guangzhou, 510060, China
-
Research Site
Guangzhou, 510515, China
-
Research Site
Harbin, 150081, China
-
Research Site
Nanning, 530021, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Hong Kong, 999077, Hong Kong
-
Research Site
Shatin, 00000, Hong Kong
-
Research Site
Florence, 50134, Italy
-
Research Site
Milan, 20132, Italy
-
Research Site
Naples, 80131, Italy
-
Research Site
Rozzano, 20089, Italy
-
Research Site
Chūōku, 104-0045, Japan
-
Research Site
Kashiwa, 277-8577, Japan
-
Research Site
Yokohama, 241-8515, Japan
-
Research Site
Seongnam-si, 463-712, South Korea
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Barcelona, 08036, Spain
-
Research Site
Barcelona, 8035, Spain
-
Research Site
Madrid, 28007, Spain
-
Research Site
Madrid, 28040, Spain
-
Research Site
Pamplona, 31008, Spain
-
Research Site
Kaohsiung City, 80756, Taiwan
-
Research Site
Kaohsiung City, 833, Taiwan
-
Research Site
Liuying, 736, Taiwan
-
Research Site
Taichung, 40705, Taiwan
-
Research Site
Tainan, 70403, Taiwan
-
Research Site
Taipei, 10002, Taiwan
-
Research Site
Taoyuan, 333, Taiwan
-
Research Site
Cambridge, CB2 0QQ, United Kingdom
-
Research Site
London, NW3 2QG, United Kingdom
-
Research Site
Manchester, M20 4BX, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can a smart drug home in on Hard-to-Treat cancers?